Codiak BioSciences, an early stage biotech developing novel exosome therapeutics for cancers, raised $83 million by offering 5.5 million shares at $15, the midpoint of the $14 to $16 range.
Codiak BioSciences plans to list on the Nasdaq under the symbol CDAK. Goldman Sachs, Evercore ISI, and William Blair acted as joint bookrunners on the deal.
